Kirit M. Ardeshna

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack et al. · The Lancet · 2013 · 556 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

The PI3 kinase, p38 SAP kinase, and NF-κB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte–derived dendritic cells

Kirit M. Ardeshna, Arnold Pizzey, Stephen Devereux et al. · Blood · 2000 · 427 citations

Life Sciences, Cell Biology, Immunology +16

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 417 citations

Medicine, Oncology, Pharmacotherapy +10

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · The Lancet Oncology · 2014 · 388 citations

Medicine, Oncology, Pharmacotherapy +8

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Ian W. Flinn, Carole B. Miller, Kirit M. Ardeshna et al. · Journal of Clinical Oncology · 2019 · 264 citations · Full text

Medicine, Oncology, Pharmacotherapy +13